Physician profile
Alfredo Lopez
NPI 1750307831
$7,038.38
in general payments reported to CMS, 2019-2025
31 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,043 · 2020: $896 · 2021: $724 · 2022: $1,086 · 2023: $1,039 · 2024: $801 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,118 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,117.63 |
| Education | $170.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,045.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $994.76 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $732.43 | 2021-2025 | |
| Lilly USA, LLC | $544.48 | 2019-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $542.34 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $470.33 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $430.65 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $359.69 | 2021-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $356.95 | 2019 | |
| Bard Peripheral Vascular, INC. | $302.31 | 2019-2021 | |
| Pfizer INC. | $221.24 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $201.87 | 2019 | |
| Glaxosmithkline, LLC. | $165.43 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Kowa Pharmaceuticals America, INC. | $99.51 | 2020-2023 | Seglentis, Livalo |
| Allergan, INC. | $79.45 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $58.30 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.37 | 2023-2025 | Xifaxan, Trulance |
| Horizon Therapeutics Plc | $49.48 | 2019 | |
| Corium, LLC | $45.27 | 2024 | Azstarys |
| Paratek Pharmaceuticals, INC. | $42.86 | 2021-2022 | |
| Abbott Laboratories | $39.38 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $29.86 | 2024 | Rexulti |
| Vertex Pharmaceuticals Incorporated | $27.50 | 2025 | |
| Ucb, INC. | $26.95 | 2021 | |
| Amgen INC. | $25.96 | 2020-2021 | |
| Exact Sciences Corporation | $18.02 | 2024 | Cologuard Collection Kit |
| Radius Health, INC. | $16.23 | 2019 | |
| Redhill Biopharma INC. | $16.23 | 2021 | |
| Dexcom, INC. | $14.84 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $11.80 | 2022 | |
| Si-Bone, INC. | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfredo Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.